Pcn92 - The Evaluation of the Economic Efficiency of Lenvatinib in Combination With Everolimus in Russian Patients With Disseminated Renal Cell Carcinoma

Value in Health- United Kingdom

doi 10.1016/j.jval.2018.09.174

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Efficacy and Safety of Lenvatinib in Combination With Everolimus in Metastatic Renal Cell Carcinoma Resistant to Antiangiogenic Targeted Therapy: Russian Multicenter Observational Study ROSLERCM

Onkourologiya
OncologyRadiologyUrologyNuclear MedicineNephrologyImagingSurgery
2019English

Molecular Markers Associated With the Response to Therapy With Everolimus in Patients With Renal Cell Carcinoma

Siberian Journal of Oncology
Cancer ResearchOncology
2016English

Clinical Experience and Critical Evaluation of the Role of Everolimus in Advanced Renal Cell Carcinoma

Research and Reports in Urology
Urology
2011English

A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

Outcomes Based on Age in the Phase III METEOR Trial of Cabozantinib Versus Everolimus in Patients With Advanced Renal Cell Carcinoma

European Journal of Cancer
Cancer ResearchOncology
2020English

Everolimus &Ndash; A New Approach in the Treatment of Renal Cell Carcinoma

Cancer Management and Research
Oncology
2010English

Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma

European Urology
Urology
2016English

Phase 2 Study of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Journal of Gastroenterology
Gastroenterology
2016English

Prognostic Factors in Patients With Renal Cell Carcinoma

Japanese Journal of Urology
Urology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy